RoActemra 20mg/ml ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 40 | Takayasu arteritis | 1 |
40. Takayasu arteritis
Clinical trials : 25 / Drugs : 50 - (DrugBank : 21) / Drug target genes : 25 - Drug target pathways : 114
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-003753-13-FR (EUCTR) | 19/03/2019 | 13/12/2018 | INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis | Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: RoActemra 20mg/ml Product Name: Tocilizumab INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB Product Name: Infliximab INN or Proposed INN: INFLIXIMAB | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 3 | France |